Sonnet Biotherapeutics Holdings Stock Number Of Shares Shorted
| SONN Stock | USD 1.54 0.02 1.32% |
Sonnet Biotherapeutics Holdings fundamentals help investors to digest information that contributes to Sonnet Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Sonnet Stock. The fundamental analysis module provides a way to measure Sonnet Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sonnet Biotherapeutics stock.
Sonnet |
Sonnet Biotherapeutics Holdings Company Number Of Shares Shorted Analysis
Sonnet Biotherapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Sonnet Biotherapeutics Number Of Shares Shorted | 62.47 K |
Most of Sonnet Biotherapeutics' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sonnet Biotherapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Sonnet Biotherapeutics Holdings has 62.47 K of outstending shares currently sold short by investors. This is 98.05% lower than that of the Biotechnology sector and 98.77% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 98.67% higher than that of the company.
Sonnet Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sonnet Biotherapeutics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sonnet Biotherapeutics could also be used in its relative valuation, which is a method of valuing Sonnet Biotherapeutics by comparing valuation metrics of similar companies.Sonnet Biotherapeutics is currently under evaluation in number of shares shorted category among its peers.
Sonnet Fundamentals
| Return On Equity | -2.65 | ||||
| Return On Asset | -0.97 | ||||
| Operating Margin | (219.69) % | ||||
| Current Valuation | 4.55 M | ||||
| Shares Outstanding | 3.01 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Number Of Shares Shorted | 62.47 K | ||||
| Price To Book | 2.07 X | ||||
| Price To Sales | 82.88 X | ||||
| Revenue | 18.63 K | ||||
| Gross Profit | (6.33 M) | ||||
| EBITDA | (11.85 M) | ||||
| Net Income | (7.44 M) | ||||
| Cash And Equivalents | 5.22 M | ||||
| Cash Per Share | 1.21 X | ||||
| Total Debt | 130.86 K | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 1.10 X | ||||
| Book Value Per Share | 4.01 X | ||||
| Cash Flow From Operations | (8.61 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (11.35) X | ||||
| Target Price | 160.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 4.63 M | ||||
| Total Asset | 2.77 M | ||||
| Retained Earnings | (117.68 M) | ||||
| Working Capital | (786.37 K) | ||||
| Net Asset | 2.77 M |
About Sonnet Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sonnet Biotherapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sonnet Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sonnet Biotherapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock: Check out Sonnet Biotherapeutics Piotroski F Score and Sonnet Biotherapeutics Altman Z Score analysis. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.